A Comparison Of P&R Requirements For Orphan Drugs In 25 Markets

October 4, 2018 Danielle Twigg

Companies have historically been unwilling to invest in new treatments for rare diseases; small patient populations limit revenue potential. In response, countries have enacted legislation to encourage drug development in such orphan indications that provides developmental and regulatory incentives. However, the reimbursement/payer hurdle is increasingly becoming the key challenge to overcome in terms of patient access and commercial success. The objective of this research was to understand how orphan drugs (ODs) undergo pricing and reimbursement (P&R) across 25 major and emerging markets.

Authors: Macaulay R, Roibu C, Ivanova H, Campbell J, PAREXEL International, London, United Kingdom

To find out more about this poster you can register to download it here after the ISPOR event.

 

Previous Article
Less Haste, More Speed? Do European Accelerated Authorisations Translate Into Early Reimbursement And Patient Access?
Less Haste, More Speed? Do European Accelerated Authorisations Translate Into Early Reimbursement And Patient Access?

Next Article
Making Sense From Anti-Sense: Lessons In Translating Expedited Regulatory Approval Into Reimbursement And Commercial Success
Making Sense From Anti-Sense: Lessons In Translating Expedited Regulatory Approval Into Reimbursement And Commercial Success